SLC6A3 and attention deficit-hyperactivity disorder: Abnormal DAT availability in humans with neuropsychiatric disorders has been reported [14, 15] and first line treatments for ADHD, i.e., methylphenidate and alpha-methylphenethylamine (d-amphetamine) formulations [16] exhibit high affinity towards DAT [11] and modulate extracellular DA in human subjects [17].